Oregon Health & Science University has been involved in the drug’s clinical trials and its subsequent FDA approval since 2014, when Richard Maziarz, M.D., former medical director of the adult blood and marrow stem cell transplant and now leader of the immune effector cellular therapy program in the OHSU Knight Cancer Institute, was named as co-principal investigator of the trial, along with Stephen J. Schuster, M.D., of the University of Pennsylvania.

“This is the final, long-term analysis of the JULIET trial—one of the earliest CAR-T studies in the U.S.,” Maziarz said. “We’re now identifying many survivors six years out, which is remarkable for a population that had very few options and very limited expectations for any meaningful survival.”